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Background: Angiotensin II type 1 receptor (AT1R) blockers have beneficial effects on neurovascular complications
in diabetes and in organ’s protection against ischemic episodes. The present study examines whether the AT1R
blocker candesartan (1) has a beneficial effect on diabetes-induced alteration of pressure-induced vasodilation (PIV,
a cutaneous physiological neurovascular mechanism which could delay the occurrence of tissue ischemia), and (2)
could be protective against skin pressure ulcer formation.
Methods: Male Swiss mice aged 5–6 weeks were randomly assigned to four experimental groups. In two groups,
diabetes was induced by a single intraperitoneal injection of streptozotocin (STZ, 200 mg.kg−1). After 6 weeks,
control and STZ mice received either no treatment or candesartan (1 mg/kg-daily in drinking water) during
2 weeks. At the end of treatment (8 weeks of diabetes duration), C-fiber mediated nociception threshold,
endothelium-dependent vasodilation and PIV were assessed. Pressure ulcers (PUs) were then induced by pinching
the dorsal skin between two magnetic plates for three hours. Skin ulcer area development was assessed during
three days, and histological examination of the depth of the skin lesion was performed at day three.
Results: After 8 weeks of diabetes, the skin neurovascular functions (C-fiber nociception, endothelium-dependent
vasodilation and PIV) were markedly altered in STZ-treated mice, but were fully restored by treatment with
candesartan. Whereas in diabetes mice exposure of the skin to pressure induced wide and deep necrotic
lesions, treatment with candersartan restored their ability to resist to pressure-induced ulceration as efficiently as
the control mice.
Conclusion: Candesartan decreases the vulnerability to pressure-induced ulceration and restores skin neurovascular
functions in mice with STZ-induced established diabetes.
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Diabetes is a particularly important risk factor for the
development of chronic wounds because it is often as-
sociated with vasculopathy and neuropathy. Diabetic
neuropathy (DN) is a common complication of diabetes
mellitus (DM). Many of diabetic patients develop a DN,
most commonly seen as distal symmetrical sensorimotor* Correspondence: claire.demiot@unilim.fr
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unless otherwise stated.polyneuropathy [1]. Diabetic patients who express DN
tend to develop spontaneous skin injury as diabetic foot
ulcer. The common understanding is that sensory nerve
impairment diminishes the perception of pain that is pro-
tective when tissue injury occurs. Patients are not aware
of pain, and lose protective withdrawal reflex to avoid tis-
sue harm. While this certainly remains true, we recently
reported that, for the same imposed unavoidable pressure
stimulus, diabetic mice develop more severe skin ulcer-
ation than healthy control mice, indicating that in diabetic. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tive protection against ischemic pressure are impaired [2].
Pressure-induced vasodilation (PIV) was reported as a
physiological neurovascular response to local application
of low pressure to the skin that increases cutaneous
blood flow, thereby delaying the occurrence of tissue
ischemia, and thus protecting the skin against pressure
[3,4]. The cutaneous neuronal mechanosensor initiating
the vasodilatory response has recently been identified as
the Acid-sensing ion channel 3 (Asic3), a mechanosensi-
tive channel [5]. The succession of steps leading to PIV
involves pressure perception in nociceptive sensory small
fibers neurons mediated by Asic3, resulting in release of
the vasodilator calcitonin gene-related peptide (CGRP)
from afferent sensory nerve endings. CGRP then triggers
the liberation from the endothelium of nitric oxide (NO)
that is responsible for vascular smooth muscle cell relax-
ation. Hence, a normal PIV response requires both the
functional integrity of small fibers sensory neurons and
endothelium-dependent relaxation, which are both al-
tered by diabetes. Indeed, PIV is impaired in experimen-
tal models of diabetes in mice [6], as well as in diabetes
patients [7], reflecting the vulnerability of diabetic skin
to pressure.
Overwhelming evidence has accumulated showing that
activation of the tissue renin-angiotensin system (RAS)
is involved in the alteration of endothelium-dependent
relaxation in diabetes and that blockade of the RAS has
beneficial effects on endothelial function. Successful
clinical trials have established opposing the RAS, with
either ACE (Angiotensin-converting enzyme) inhibitors
(ACEIs) or angiotensin-receptor blockers (ARBs), as first
line treatment not only for hypertension, but also for
prevention of cardiovascular disease, nephropathy and
retinopathy in diabetic patients [8].
Although more scarcely studied, experimental animal
studies also suggest a beneficial effect of RAS blockade
on diabetic neuropathy. ACEIs or ARBs improve neural
functions in streptozotocin-diabetes rats [9-12] and the
ARB olmesartan has been shown to improve peripheral
nerve dysfunction in Zucker diabetic fatty rats [13].
Clinical data are very limited, but a double-blind con-
trolled trial conducted in 41 normotensive type I or II
diabetes patients with mild neuropathy suggested a
beneficial effect of the ACEI trandolapril on peripheral
neuropathy [14]. The double protective action of RAS
blockade towards diabetes induced endothelial dys-
function and peripheral neuropathy thus raised the hy-
pothesis that it might be well suited for preventing
diabetes induced PIV impairment, allowing the skin to
resist to pressure-induced ischemia. The present study
was thus designed to determine whether the ARB
candesartan, administered in long-term streptozotocin-
diabetic mice with established neurovascular dysfunction,could restore PIV and prevent pressure-induced skin ulcer
formation.
Methods
Experimental groups of treatment
Male Swiss mice aged 5–6 weeks (20-25 g) were ob-
tained from Depré (Saint Doulchard, France), and
maintained on a 12 h light/dark cycle with food and
water available ad libitum. Mice were randomly
assigned to 4 experimental groups (n = 80, so 20 per
group). In two groups, diabetes was induced by a single
intraperitoneal injection of streptozotocin (STZ)
(200 mg.kg−1; Sigma-Aldrich, Lyon, France), whereas
in the two control groups the mice received an intra-
peritoneal injection of the vehicle (citrate buffer,
pH 4.5). In the diabetic groups hyperglycemia occurred
2 days after STZ injection and was verified using Accu-
Check Active glucometer (Roche, Lyon, France). Mice
were excluded when blood glucose was < 288 mg.dl−1
two days after injection. After 6 weeks of diabetes
duration, one control and one STZ group were left
untreated, while the other control group and the other
STZ group were treated with candesartan (Astra-Zeneca,
1 mg.kg−1 per day in drinking water) for two add-
itional weeks (Figure 1). The concentrations of can-
desartan in drinking water were adapted according
to the daily water quantity absorbed by the mice in
order to insure each mouse received approximately
1 mg.kg−1 per day.
Assessments of mechanical nociception, skin microcir-
culation reactivity and cutaneous neurovascular func-
tions, and induction of ulcer formation by pressure,
were then performed after 8 weeks of diabetes. The sta-
bility of cutaneous temperature and systolic arterial
blood pressure were controlled throughout the experi-
ments of skin microcirculation reactivity and cutaneous
neurovascular functions.
All experiments were carried out according to protocols
approved by the Ethics Committee of Animal Experiments
of Limousin (CREEAL-n°1-2013-2). The current inves-
tigation conformed to the guidelines for ethical care of
experimental animals of the European Community
and was approved by the French Agriculture Ministry
(authorization n°87-019).
Mechanical pressure algesia
Tail pressure thresholds were registered with the Paw/Tail
Pressure Analgesia meter for the Randall-Selitto test (Bio-
seb, Vitrolles, France). Pressure increasing at a linear rate
of 16 g s−1, with a cut-off at 250 g to avoid tissue injury,
was applied to the base of the tail. The applied tail pres-
sure that evoked biting and licking behaviour was regis-
tered and expressed in grams. Three tests separated by at
least 15 minutes were performed for each animal.
Figure 1 Schematic representation of study design. PU: pressure ulcer, STZ: streptozotocin.
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Hair of the animals was removed 2 days before ex-
periments, with a depilatory lotion to obtain a hair-
less area for skin Laser Doppler Flowmetry (LDF)
measurements, local pressure application, and ionto-
phoretic delivery. For experiments, animals were anesthe-
tized with thiopental sodium (65 mg.kg−1intraperitoneal)
and then placed in an incubator (Mediprema, Tours,
France) warmed to maintain a stable cutaneous
temperature (35.0 ± 0.5°C). Non-invasive tail blood
pressure (Bionic Instruments, Tokyo, Japan) was recorded
before and after experiments to verify systolic arterial
blood pressure (SABP) stability.Skin microcirculation reactivity: Endothelium-independent
and –dependent responses
Skin blood flow was recorded, using a laser Doppler
multifiber probe (481–1; Permied, Stockholm, Sweden)
during transcutaneous iontophoresis applied to a 1.2 cm2
area on the hairless back of animals. Skin blood was re-
corded at baseline, and during anodal acetylcholine (Ach)
iontophoretic delivery (endothelium-dependent vasodila-
tion assessment) or cathodal sodium nitroprusside (SNP)
iontophoretic delivery (endothelium-independent vasodila-
tion assessment) as previously described [15]. Vasodilator
responses were reported as the maximal percentage in-
crease from baseline in response to Ach orSNP.Skin neurovascular reactivity: Pressure-induced
vasodilation
Skin blood flow in response to local pressure was
measured by LDF, as previously described [3]. A laser
Doppler probe (PF408, Periflux; Permied) was con-
nected to a laser Doppler flowmeter (PF5000 Master,
Periflux; Permied). The probe was placed in the mid-
dle of the hairless skull and external pressure was
increased progressively at 2.2 Pa.s−1 through the probe.
The LDF signal was digitized with 20 Hz sampling
frequency, using a computerized acquisition system
(Biopac, Santa Barbara, CA). Data collection startedafter a 1-min equilibration period before the onset of
increasing pressure.
Pressure ulcer model
Pressure ulcers were created on the dorsum of mice as
described elsewhere [2,16]. The dorsal hair was shaved.
After 24 h, the skin (epidermis, dermis and subcutane-
ous tissue layer, but not muscles) was pinched between
two magnetic plates (10 mm diameter and 1 mm thick,
with an average weight of 0.5 g and 10,000 Gauss mag-
netic force). This process created a compressive pres-
sure of approximately 2,000 mmHg between the two
magnets. Applying the magnets for 3 h had been shown to
reproducibly elicit a skin ulcer in diabetic mice, but to
only induce inconstant and minimal lesions in normal
mice [2]. Skin ulcers develop progressively after with-
drawal of the magnets, peaking at day three.
Analysis of pressure ulcer formation
Each compressed area was photographed daily during
three days using a 3.3 megapixel camera (Photo PC
3100Z; Epson, Nagano, Japan). Pressure ulcers were
staged by visual assessment according the standardized
ulcer scale [17]. Skin ulcer area percentage was calcu-
lated in the total compressed area using an image
analyzer (Clara Vision, Orsay, France).
At day three tissue samples were dissected from the
center of the lesion for a microscopic analysis. Samples
were fixed overnight in buffered 4% formaldehyde solu-
tion, embedded in Finetek Tissu-Tek compound, and
then frozen at −20°C. Sections of 12 μm were stained
with hematoxylin and eosin. The samples were analyzed
with an optical microscope (Leica).
Histological examination was based on histological
modifications of the three skin layers and lack of tissue
depth in the center of the sections (score 0: no histological
modification of the three skin layers; score 1: three skin
layers with disruption of fibers and histological epidermis
modification; score 2: epidermal defect with necrotic areas
in dermis; score 3: superficial dermal defect with necrotic
regions; and score 4: deep dermal defect).
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Prism version 6.04 (GraphPad Software, Inc.; LaJolla,
CA, USA) was used to make graphs and perform statis-
tical tests. All data are presented as mean ± SE. A one-
way analysis of variance (ANOVA) was used to evaluate
differences among multiple groups with p values deter-
mined by the Newman-Keuls multiple range test with
Gaussian distribution. A non-parametric Kruskal-Wallis
test and Dunn’s multiple comparisons test were used for
data which did not follow a Gaussian distribution. Dif-




Whereas after 8 weeks the control mice almost doubled
their body weight, induction of diabetes markedly re-
duced the weight gain. Interestingly, candesartan had no
effect on the blood glucose levels, although it did have
an incomplete favourable effect on weight gains in the
diabetic mice. Neither treatment with candesartan nor
the diabetes induction significantly changed the systolic
arterial blood pressure (Table 1).
Effects of candesartan on nociceptive, skin
microcirculation and neurovascular function
Assessment of mechanical algesia
After 8 weeks of diabetes, the tail pressure Randall-
Sellito test evidenced a significant mechanical hypoalge-
sia in untreated diabetic mice (Figure 2a). The mechan-
ical nociceptive threshold was enhanced in untreated
diabetic mice (192.2 ± 19.22 g versus 126.5 ± 7.4 g in
controls, p < 0.05), but was restored in the candesartan-
treated diabetic group to the level of its respective con-
trol group (157.1 ± 6.1 g versus 141.6 ± 8 g, NS).
Assessment of endothelium-independent and -dependent
responses
Assessment of endothelium-dependent response
In the untreated control group, iontophoretic delivery
of ACh increased LDF, corresponding to a maximal
vasodilation of 33.3 ± 7.3%. Diabetes markedly blunted
endothelium-dependent vasodilation to 8.6 ± 2.5%, (p < 0.01
versus Control). Treatment of the diabetic mice with can-
desartan significantly improved the ACh-induced vaso-
dilation(31.3 ± 5.8%, p < 0.05 versus Diabetic) and restoredTable 1 Effects of diabetes and candesartan on weight gain, b
Groups Control Diabetic
Body weight gain (g) 22.25 ± 0.86 4.94 ± 1.1
Blood glucose (mg/dL) 130.3 ± 7.94 466.7 ± 39
SABP (mmHg) 64.33 ± 3.38 73.58 ± 5.
SABP: systolic arterial blood pressure. (n = 10 in each group, 1-way ANOVA followed
between candesartan-treated mouse group and respective untreated mouse groupto the level of the non diabetic control groups (NS versus
Control) (Figure 2b).
Assessment of endothelium-independent response
In all groups, LDF increased in response to iontophoretic
delivery of sodium nitroprusside, and the endothelium-
independent vasodilatory response was similar in the four
groups of mice (data not shown).
Assessment of pressure-induced vasodilation
In the control mice, the progressive increase in local
pressure application elicited the normal biphasic PIV re-
sponse, i.e. a progressive increase in LDF peaking at 0.4
kPa then reversing to a progressive decrease, with a
maximal vasodilatory response of 34.7 ± 8.4% (Figure 2c).
In contrast, the normal PIV response was abolished in
the untreated diabetic mice, resulting in a negative
change of LDF from baseline at 0.4 kPa (−16.7 ± 6.5%,
p < 0.001 versus Control) (Figure 2c). Treatment with
candesartan had no effect in control mice (34.1 ± 8%),
and fully restored a normal PIV response in diabetic
mice (27.73 ± 10.5%, p < 0.05 versus Diabetic, NS versus
Control) (Figure 2d).
Effects of candesartan on pressure-induced ulcer
formation
Exposure to pressure of the back skin in control mice elic-
ited modest and inconstant skin lesions (Figure 3a, b).
After three days, the mean lesion surface was 3.3 ± 1.5%
of the compressed area. Histological examination of the
lesion center showed a thickening of the epithelium with
the remaining presence of three skin layers, yielding a
score of 1 ± 0.02. The diabetic mice developed larger and
much severe lesions: the mean ulcer area was 21.9 ± 2.3%,
and histological examination mainly showed epidermal
and dermal necrotic defects with a score of 2.9 ± 0.35
(Figure 4a, b). Treatment with candesartan completely
restored the ability of the diabetic skin to resist to
pressure-induced ischemia/reperfusion injury, as the
size and the depth of the lesions were similar to that ob-
served in the non-diabetic controls.
Discussion
The main findings of our study are that the ARB cande-
sartan, administered for two weeks in mice with diabetes
of six weeks duration with established neuropathy (1)lood glucose and SABP
Candesartan Diabetic + Candesartan
0*** 19.25 ± 2.20 10.25 ± 1.36***
.08 120.5 ± 5.09 461.4 ± 44.04
88 66.71 ± 4.93 64.92 ± 4.28
by Newman-Keuls’s post-hoc test, ***P < 0.001: significance of the difference
).
Figure 2 Effects of candesartan on nociceptive, skin microcirculation and neurovascular function. (a) Randall-Sellito tail pressure test.
Mechanical withdrawal thresholds to nociceptive tail pressure. (b) Endothelium-dependent vasodilation. Maximal percentage of vasodilation from
baseline in response to iontophoretic delivery of Ach. (c) Cutaneous typical laser Doppler blood flow response during a progressive increase of
pressure in a control mice (black) and in a diabetic mice (red). P: start of pressure, a.u.: arbitrary units. (d) Pressure-induced vasodilation. Maximal
percentage of vasodilation from baseline during localpressure application. (n = 10 in each group,non-parametric Kruskal-Wallis test followed by
Dunn’s post-hoc test, *P < 0.05, **P < 0.01, ***P < 0.001)Ach: Acetylcholine, LDF:Laser Doppler Flowmetry.
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functional nociceptive hypoalgesia, and fully restored a
normal PIV response, and (2) restored the ability of the
diabetes mice skin to resist to pressure-induced ischemia
as efficiently as in the control mice.Figure 3 Effect of candesartan on cutaneous macroscopic findings fo
compressed areas, one day and three days after pressure release. Scale bar
each group, non-parametric Kruskal-Wallis test followed by Dunn’s post-hocEffect of candesartan on endothelial function
The beneficial effect of candesartan on endothelial func-
tion in diabetes has been documented by more than two
decades and is not a novel finding. The understanding
that activation of the RAS during diabetes increasellowing 3 hours of pressure. (a) Representative photographs of skin
= 2 mm (b) Time course of macroscopic stage 2 ulcer area. (n = 20 in
test, ***P < 0.001).
Figure 4 Effect of candesartan on histological findings following 3 hours of pressure. (a) Representative photographs of central
histological skin compressed section, one day and three days after pressure release. Ischemic skin lesions were removed 24 h and 72 h after
pressure release and stained with hematoxylin and eosin. ep: epidermis, d.pl: dermis-papillary layer, d.rl: dermis-reticular layer. Scale bar = 100 μm.
(b) Central histological pressure score (n = 6 in each group, *P < 0.05).
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synthase from an NO-producing enzyme to an enzyme
that functions as a NADPH oxidase, and generates
superoxide and hydrogen peroxide, has been widely doc-
umented. This process, termed NOS uncoupling, result-
ing in less NO and more superoxide generation, has
been established as a central underlying cause of endo-
thelial dysfunction found in atherosclerosis, hyperten-
sion, diabetes and ischemia/reperfusion [18,19]. Evidence
has accumulated, both in experimental models [20-23]
and clinical studies [24-29], in a broad variety of vascular
beds and organs, that reducing the RAS activation,
either with ACE inhibitors or ARBs, reduces inflamma-
tion, improves endothelial dysfunction caused by hyper-
tension and/or diabetes, recouples eNOS and restores
NO availability. Although not documented in our study,
it makes thus little doubt that the beneficial effect of
candesartan on endothelial function was linked to the
improvement of the well-established effect of ARBs on
diabetes-induced imbalance of NO and ROS production
in the skin vasculature. Accordingly, the effects of can-
desartan herein reported likely reflect a class effect.
However, some heterogeneity among the various sartans
has been reported [30] and further studies are requiredto confirm that our results reflect a generic property of
AT1 blockade and are not restricted to candesartan.
Effect of candesartan on sensory neuropathy
Like diabetic patients, mice with streptozotocin-induced
diabetes develop peripheral diabetic neuropathy with
alterations in nociceptive thermal and mechanical
thresholds [31] corresponding to a deterioration of small
sensory fibers (C and Aδ fibers); the first fibers affected in
diabetic neuropathy [32]. In Swiss mice, thermal hypoalge-
sia develops after only two weeks of streptozotocin-
induced diabetes and deficit of intraepidermal nerve
fiber density is present after 4 weeks [33]. In our study,
Candesartan restored a normal nociceptive threshold
in diabetic mice with 8 weeks of diabetes in accordance
with reported evidence supporting a beneficial effect of
opposing angiotensin II in diabetic neuropathy. Experi-
mental [12] and clinical data [14,34] suggest that
ACEIs have beneficial effects on diabetic neuropathy.
Directly opposing angiotensin II with AT1 blockade
has been similarly reported to ameliorates intraepider-
mal fiber density in type 2 diabetic rat [13], and to im-
prove sciatic epineurial arteriole reactivity, preventing
neuronal ischemia [12] in streptozotocin-diabetic rats.
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RAS blockade on diabetic neuropathy remain unclear,
both the improvement of vascular function and the re-
duction of oxidative stress and inflammation have been
proposed to be involved [12].
Candesartan restored a normal PIV and the ability of
the diabetic mice skin to resist to pressure-induced
ischemia. As anticipated, the restoration of both endo-
thelial function and nociceptive perception restored a
normal PIV response in our model. This was associated
with a fully restored capacity of the diabetic mice to
resist of pressure-induced skin ulcer. The question how-
ever remains as to whether the later is a direct conse-
quence of the former.
Fromy et al. [5] have established a direct causative link
between PIV and the skin ability to resist to pressure in-
duced ulceration, by demonstrating that genetically
modified mice lacking Asic3, in contrast to their wild
type controls, have a defective PIV and develop skin
ulcer after exposure to pressure. Because the pressure
applied to the skin was orders of magnitude higher than
the threshold pressure value that elicits the maximal
vasodilatory response, skin perfusion was completely
suppressed under the magnets, whether PIV was present
or not. The authors showed that, skin blood flow rapidly
recovered after pressure release in the control mice, but
not in the Asic3−/− mice. The proposed explanation is
that Asic3 is not only a mechanosensitive channel, but is
also activated by protons and lactates. The rapid reperfu-
sion and reoxygenation of the skin would thus reflect
the vasodilatory response to ischemia-induced tissular
acidification, lacking in Asic3−/− mice. PIV thus can be
viewed as a surrogate functional marker, allowing a
simple and non-invasive assessment of the integrity
of a physiological mechanism involving post-ischemia
acidification-induced hyperemia, a necessary condition
to allow the normal skin to resist to pressure ulcer. It is
thus tempting to speculate that in our study, the restor-
ation of a normal PIV by candesartan was necessary and
sufficient for allowing the skin of the diabetic mice to re-
sist to pressure ulcer, but this cannot be concluded with
certainty. Indeed, in the very same experimental model,
we have previously shown that treatment with recombin-
ing human erythropoietin (rhEPO) restored skin innerv-
ation density and C-fiber nociception and fully prevented
pressure ulcer development in diabetic mice [2]. However,
rhEPO had no effect on endothelial dysfunction and failed
to restore a normal PIV. It is therefore possible that the
protection against pressure ulcer by candesartan, like
rhEPO, targets a mechanism of protection against
ischemia-reperfusion, bypassing its beneficial effect on
PIV.
Importantly, whereas ACE inhibitors decrease Ang II
circulating levels, blockade of the AT1 receptor has theopposite effect. By blunting the AT1-mediated negative
feedback of angiotensin II on renin release, it results in
increased circulating levels of angiotensin II and its ca-
tabolites, angiotensin III and angiotensin IV, leading to
increased stimulation of unopposed AT2 and AT4
(IRAP) receptors [35]. A protective effect of ARBs in
cerebral ischemia has been largely documented, and has
been shown to be dependent upon non-AT1 receptors
[36-43], whereas ACE inhibition was deleterious or inef-
fective [37,39,43,44]. Therefore, a central question raised
by our present findings is whether the skin protective
effect of candesartan in the present study is solely the
consequence of reducing the stimulation of AT1 by
angiotensin II (AngII), or if it involves ARB induced
non-AT1 mechanisms. Further studies are required to
elucidate the mechanism of the protective effect of can-
desartan against pressure-induced skin ischemia, and a
direct head to head comparison with the effect of ACE
inhibition clearly appears as the first step.
As recalled above, ACE inhibitors share the protective
effect of ARBs against diabetes induced endothelial dys-
function and peripheral neuropathy, and would thus be
expected to be as effective to restore PIV. However it is
possible that, despite restoring a normal PIV, ACE inhib-
itors fail to restore the diabetes skin ability to resist to is-
chemia, if this later effect depends upon non-AT1
receptors activation. Indeed, a recent study by Margolis
et al. [45] supports this hypothesis. In this retrospective
cohort study conducted in 40,000 individuals with dia-
betes treated with either ACE inhibitors or ARBs, the
risk of foot ulcer, and the risk of lower limb amputation
for those with peripheral arterial disease were both twice
higher for those on ACE inhibitors. Although the intrin-
sic limitations inherent to population based retrospective
cohort studies preclude a definitive conclusion, this im-
pressive difference in foot ulcer risk makes the hypoth-
esis worth considering.
Whether the restoration of a normal PIV is involved
or not, the most salient finding of our study is that in
the murine model of streptozotocin-induced diabetes, a
rescue treatment with a non-hypotensive dose of cande-
sartan administered for 2 weeks after 6 weeks of diabetes
was able to prevent the development of deep skin ulcers
in response to an imposed pressure insult, a finding that
may open to important therapeutic perspectives. Cer-
tainly, further preclinical studies are mandatory to rep-
licate our findings in other models of experimental
diabetes, but such independent confirmation of our re-
sults would strongly invite to consider implementing a
clinical trial to evaluate the protective effect against
foot ulcerations of early ARB treatment in normoten-
sive non-albuminuric diabetes patients. Indeed, the in-
cidence of diabetes and its complications is increasing
worldwide, and the lifetime prevalence of foot ulcers is
Danigo et al. Cardiovascular Diabetology  (2015) 14:26 Page 8 of 9estimated to 10 to 20% [46,47] with devastating conse-
quences for the patients and a considerable economic
burden for the health care systems, whereas ARBs
treatment are relatively inexpensive and have been
largely demonstrated to be safe, well tolerated and
beneficial in diabetic patients.
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